Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

"With over 11,500 prostate cancer deaths every year in the UK alone, and few alternative treatments, there is an urgent need to make new and improved treatments available," said AAA's general ...

PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine, 385(12), 1091–1103.

positive metastatic castration-resistant prostate cancer (mCRPC). Novartis Pharmaceuticals Canada Inc. (CNW Group/Novartis Pharmaceuticals Canada Inc.) "Ensuring Nova Scotians have access to the ...